

DEC 09 2004

Please type a plus sign inside this box +

ATO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet

2

of | 1

1

Application Number	10/728,491
Filing Date	December 5, 2003
First Named Inventor	Wang et al.
Group Art Unit	1635
Examiner Name	ZARIA
Attorney Docket Number	11520.0338

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J3	1	STEIN et al., <i>Phosphorothioate Oligodeoxynucleotide Analogues, Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, Topics in Molecular and Structural Biology</i> (1989) Volume 12, pp. 97-117	

Examiner Signature  **Date Considered** **11-30-06**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/728,491	
Sheet	2	of	3	Filing Date	December 5, 2003
				First Named Inventor	Wang et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	11520.0338

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J3	1	ASHUN et al., <i>Inhibition of Murine Leukemia virus with Poly2'-O-(2, 4-Dinitrophenyl) Poly [A]</i> , Antimicrobial Agents and Chemotherapy (Oct. 1996) Vol. 40, No. 10, pp. 2311-2317	
	2	BRADBURY et al., <i>Protein Kinase A (PK-A) Regulatory Subunit Expression in Colorectal Cancer and Related Mucosa</i> , Brit. J. Cancer (1994) Vol. 69, pp. 738-742	
	3	CHEN et al., <i>Poly-2'-DNP-RNAs with Enhanced Efficacy for Inhibiting Cancer Cell Growth</i> , Oligonucleotides (2004) Vol. 14, pp. 90-99	
	4	CHO-CHUNG, <i>Antisense DNA Toward Type I Protein Kinase A Produces Sustained Inhibition of Tumor Growth</i> , Proceedings of the Assoc. of American Physicians (1997) Vol. 109, No. 1, pp. 23-32	
	5	KANG et al., <i>Design of Structure-Based Reverse Transcriptase Inhibitors</i> , The Journal of Biological Chemistry (April 2, 1994) Vol. 269, No. 16, pp. 12024-12031	
	6	MILLER et al., <i>Types of Cyclic AMP Binding Proteins in Human Breast Cancers</i> , Eur. J. Cancer (1993) Vol. 29A, No. 7, pp. 989-991	
	7	NESTEROVA et al., <i>A Single-Injection Protein Kinase A-Directed Antisense Treatment to Inhibit Tumour Growth</i> , Nature Medicine (June 1995) Vol. 1, No. 6, pp. 528-533	
	8	NESTEROVA et al., <i>Oligonucleotide Sequence-Specific Inhibition of Gene Expression, Tumor Growth Inhibition, and Modulation of cAMP Signaling by an RNA-DNA Hybrid Antisense Targeted to Protein Kinase A Rα Subunit</i> , Antisense & Nucleic Acid Drug Development (2000) Vol. 10, pp. 423-433	
	9	RAHMAN et al., <i>Selective Removal of Ribonucleases from Solution with Covalently Anchored Macromolecular Inhibitor</i> , Analytical chemistry (January 1, 1996) Vol. 68, No. 1, pp. 136-138	
	10	RU et al., <i>Specific Inhibition of Breast Cancer Cells by Antisense Poly-DNP-Oligoribonucleotides and Targeted Apoptosis</i> , Oncology Research (1998) Vol. 10, pp: 389-397	
✓	11	RU et al., <i>Growth Inhibition and Antimetastatic Effect of Antisense Poly-DNP-RNA on Human Breast Cancer Cells</i> , Oncology Research (1999) Vol. 11, pp. 505-512	

Examiner Signature	J3 one	Date Considered	11-30-06
--------------------	--------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

3

of 3

Application Number	10/728,491
Filing Date	December 5, 2003
First Named Inventor	Wang et al.
Group Art Unit	
Examiner Name	

Attorney Docket Number 11520.0338

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J3	12	SHEN et al., <i>A High-Efficacy Antisense Rα Poly-DNP 2'-nt RNA</i> , Antisense and Nucleic Acid Drug Development (2003) Vol. 13, pp. 67-74	
	13	SUMMERTON, <i>Intracellular Inactivation of Specific Nucleotide Sequences: A General Approach to the Treatment of Viral Diseases and Virally-Mediated Cancers</i> , J. Theor. Biol. (1979) Vol. 78, pp. 77-99	
	14	SUMMERTON et al., <i>Morpholino Antisense Oligomers: Design, Preparation, and Properties</i> , Antisense & Nucleic Acid Drug Development (1997) Vol. 7, pp. 187-195	
	15	TORTORA et al., <i>The Rα Subunit of Protein Kinase A Controls Serum Dependency and Entry into Cell Cycle of Human Mammary Epithelial Cells</i> , Oncogene (1994) Vol. 9, pp. 3233-3240	
	16	WANG, Aihong et al., <i>Effective Treatment of Murine Leukemia with Antisense Poly-2'-O-(2,4-Dinitrophenyl)-Oligoribonucleotides</i> , Antisense & Nucleic Acid Drug Development (1999) Vol. 9, pp. 43-51	
	17	WANG, Hui et al., <i>Antitumor Activity and Pharmacokinetics of a Mixed-Backbone Antisense Oligonucleotide Targeted to the Rα Subunit of Protein Kinase A After Oral Administration</i> , Proc. Natl. Acad. Sci. (November 23, 1999) Vol. 96, No. 24, pp. 13989-13994	
	18	XIN et al., <i>Treatment of Duck Hepatitis B. Virus by Antisense Poly-2'-O-(2,4-Dinitrophenyl)-Oligoribonucleotides</i> , Antisense & Nucleic Acid Drug Development (1998) Vol. 8, pp. 459-468	
	19	ZAMECNIK et al., <i>Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide</i> , Proc. Natl. Acad. Sci. (January 1978) Vol. 75, No. 1, pp. 280-284	

Examiner Signature	J3 —	Date Considered	11-30-06
--------------------	------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.